“While the majority of FDA-approved gene therapies utilize AAV (Adeno-Associated Virus), these vectors often migrate to non-target tissues, necessitating high-dose administrations. This not only increases the risk of side effects but also drives costs into the billions of won per dose,” says Moon-soo Lee, CEO of GluGene Therapeutics.
GluGene Therapeutics is a biotech innovator dedicated to overcoming these industry limitations by engineering AAV vectors that deliver genetic payloads exclusively to target cells.
CEO Moon-soo Lee first encountered AAV capsid engineering during his tenure as the head of the KOSDAQ-listed InnoTherapy, through collaborative research with Jae-Hyung Jang, Professor of Chemical and Biomolecular Engineering at Yonsei University (now CTO of GluGene Therapeutics). Foreseeing the imminent era of gene therapy commercialization, the two joined forces to establish the company.
“Our core growth engine is our ability to design AAV variants that deliver treatments with pinpoint accuracy,” Lee stated. “By securing production efficiency alongside this precision, we can drastically reduce the current exorbitant prices of gene therapies, enabling true market expansion.”
The Triple-Platform Edge: ATLAS, AIMING, and GRADE
The company’s technological foundation is built on three proprietary platforms:
– ATLAS (Precision Targeting): This delivery vehicle design technology is built on CTO Jae-Hyung Jang’s evolutionary design expertise and over 20 years of experimental data. GluGene has established a database of approximately 1 billion vector variants, allowing them to design the optimal AAV vector for specific target cells and indications.
– AIMING (AI-Driven Optimization): This platform utilizes Artificial Intelligence (AI) and Machine Learning to further enhance the tissue specificity and targeting efficiency of AAV vectors.
– GRADE (Manufacturing Excellence): A manufacturing process optimization technology that meets GMP (Good Manufacturing Practice) standards. “Low productivity and quality control are significant hurdles in the commercialization phase,” Lee explained. “We have internalized suspension culture technology at the bioreactor level and established a robust quality control system.”
A Dual-Track Business Model: Vector Licensing and Therapeutic Development
GluGene Therapeutics operates on two main pillars: Vector Business and Therapeutic Development.
In the Vector Business, the company develops customized, precision-guided AAV vectors in non-human primates (NHP) based on partner needs, followed by licensing out the final vector. The initial target is Ophthalmology (Retina). “There is a massive demand for new vectors capable of penetrating deep retinal cell layers,” Lee noted. “Based on our NHP research, we are expanding our joint development pipelines with various partners.” In the mid-to-long term, the company is also targeting neuromuscular diseases, where high-dose treatments are common, making low-dose targeting vectors essential.
Regarding Therapeutic Development, GluGene pursues both in-house and collaborative pipelines. The lead internal candidate, ‘GGT-100’, is a treatment for Pulmonary Arterial Hypertension (PAH) developed with the therapeutic gene licensed from the Chung-Ang University College of Pharmacy. The company is currently conducting NHP targeting validation and has published research in Nature-affiliated journals to boost its valuation. Recently, GluGene signed an MOU with RZNOMICS for RNA therapy co-development and secured a confidential collaboration project with a global biotech firm last year.
Building a Competitive Edge in the Global Market
“We have secured production efficiency at the pre-clinical level and internalized expertise in manufacturing, quality control, and cost competitiveness,” Lee emphasized. “We plan to offer small-scale CMO (Contract Manufacturing Organization) and quality analysis services to our collaborative partners as well.”
Through these integrated efforts, GluGene Therapeutics is not just developing treatments; it is building the vital infrastructure to make the next generation of gene therapy a reality for patients worldwide.
